Nearly 30 People in England Get Rare Illness After Botox
FDA Approves Dupixent for Bullous Pemphigoid
Benefits include sustained disease remission, reductions in itch, lower oral corticosteroids dose
ADA: Ecnoglutide Yields Superior, Sustained Reduction in Body Weight
Sustained reduction seen in body weight versus placebo for adults aged 18 to 75 with overweight or obesity, without diabetes
Quality Improvement Initiative Ups Adherence to Medical Therapy for Heart Failure
Defect-free quadruple medication therapy significantly improved at discharge, 30 days in patients with heart failure with reduced ejection fraction
FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma
Significantly improved progression-free survival seen with Monjuvi in combination with rituximab and lenalidomide
Likelihood of Psych Disorders Lower With Weight-Loss Surgery Versus GLP-1 RAs
Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery
Nearly Half With Early-Stage Breast Cancer Extend Endocrine Therapy Beyond Five Years
Decision-making was influenced by patient values and did not vary by stage, race and ethnicity, or demographics
Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes
Incidence rates of composite of death, MI, stroke were lower, but not significantly so, for patients treated with semaglutide
FDA Approves Twice-Yearly Yeztugo for Preexposure Prophylaxis to Cut HIV Risk
Approval marks first and only twice-yearly option available in the United States for PrEP
FDA Approves Once-Monthly Andembry for Hereditary Angioedema
The monoclonal antibody is a self-administered injection for prophylactic use to prevent attacks
